Core Viewpoint - Shengnuo Bio announced a voluntary disclosure of its performance forecast for the first three quarters of 2025, expecting a significant increase in net profit compared to the same period last year [1] Financial Performance - The company anticipates a net profit attributable to shareholders of the parent company between 114.20 million and 139.57 million yuan for the first three quarters of 2025 [1] - This represents an increase of 57.25 million to 82.63 million yuan compared to the same period last year, reflecting a year-on-year growth of 100.53% to 145.10% [1]

Group 1: Financial Performance - Xinhua Insurance expects a net profit of 29.986 billion to 34.122 billion yuan for the first three quarters of 2025, representing a year-on-year increase of 45% to 65% due to reforms and improved investment returns [2] - Feirongda anticipates a net profit of 275 million to 300 million yuan for the first three quarters of 2025, reflecting a growth of 110.80% to 129.96% driven by increased R&D in AI and cooling technologies [2] - Lingyi Zhizao forecasts a net profit of 1.890 billion to 2.120 billion yuan for the first three quarters of 2025, marking a growth of 34.10% to 50.42% attributed to new product launches and increased overseas revenue [5] - Yilake Co. expects a net profit of 4.300 billion to 4.700 billion yuan for the first three quarters of 2025, with a significant increase of 36.89% to 49.62% driven by rising potassium chloride prices [6] - Bojun Technology projects a net profit increase of 50% to 80% for the first three quarters of 2025 [9] Group 2: Regulatory and Corporate Actions - Fudan Zhangjiang's application for the drug Obeticholic Acid for primary biliary cholangitis was not approved by the National Medical Products Administration, with a total R&D investment of approximately 125 million yuan [3] - Northern Rare Earth received a warning letter from the Inner Mongolia Securities Regulatory Bureau for failing to disclose non-operating fund occupation by an affiliate, totaling 8.9485 million yuan [7] - Tianji Co. announced that its major shareholders reduced their holdings by 2.9996% and have terminated their reduction plan ahead of schedule [8] Group 3: Market Trends and Developments - The demand for AI server cooling solutions and related materials has increased, contributing to Feirongda's revenue growth [2] - The overall market for potassium chloride has seen price increases, positively impacting Yilake Co.'s profitability [6] - The consumer electronics market is recovering, leading to increased demand for thermal management materials, benefiting Feirongda's market share [2]

Core Viewpoint - Shengnuo Biotech (688117) expects a significant increase in net profit for the first three quarters of 2025, projecting a profit between 114 million to 140 million yuan, representing a year-on-year increase of 100.53% to 145.1% [1] Financial Performance - The company anticipates a net profit increase of 57.25 million to 82.63 million yuan compared to the same period last year [1] - The projected net profit for the first three quarters is between 114 million to 140 million yuan [1] Business Development - Shengnuo Biotech reports stable development in its main business, with continuous growth in demand for its peptide raw materials business [1] - The ongoing construction of production capacity is contributing to the sustained growth in orders, which in turn is driving overall performance improvement [1] - The company maintains strong market competitiveness and continuous profitability [1]

Company Announcements - Northern Rare Earth received a warning letter from the Inner Mongolia Securities Regulatory Bureau due to undisclosed non-operating fund occupation by related parties, amounting to 8.9485 million yuan, which has been fully repaid [2] - Aosheng Electronics reported that revenue from controllable nuclear fusion-related products will account for less than 1% of its main business revenue in the first half of 2025 [2] - Yiyi Co. is planning to acquire a pet food company, leading to a stock suspension [3] - Sanmei Co. expects a net profit increase of 172%-193% year-on-year for the first three quarters, driven by a significant rise in the average price of fluorinated refrigerants [4] - Feirongda anticipates a net profit increase of 111%-130% year-on-year for the first three quarters, with growth in AI server cooling-related business revenue [4] - Zhongshi Technology expects a net profit increase of 74%-104% year-on-year for the first three quarters, benefiting from increased shipments of thermal materials and components [4] - Juxin Technology forecasts a net profit increase of 113% year-on-year for the first three quarters, with sales revenue from edge AI processor chips increasing significantly [4] - Chuangjiang New Materials expects a staggering net profit increase of 2058%-2243% year-on-year for the first three quarters [4] - New China Life Insurance anticipates a net profit increase of 45%-65% year-on-year for the first three quarters [4] Investment & Contracts - Fostda plans to invest 1 billion yuan in the construction of an intelligent manufacturing project for marine engineering and equipment [11] Shareholding Changes - Dongxin Co. has set an initial transfer price of 82.5 yuan per share for its inquiry transfer, which is a 16% discount from the closing price [11] - China Jushi has obtained a commitment letter for a stock repurchase loan of up to 630 million yuan [12] - Tianji Co. has reduced its holdings by 2.9996% of the company's shares and has terminated its reduction plan early [3] Performance & Operations - Yingweike reported a net profit of 183 million yuan for the third quarter, an increase of 8.35% year-on-year [13] - Chenguang Biological expects a net profit increase of 344%-402% year-on-year for the first three quarters [14] - Meili Ecology's subsidiary won a bid for a 2.375 billion yuan urban renewal project in Shenzhen [18] Stock Price Movements - Hezhu Intelligent has not generated any revenue related to nuclear fusion concepts [19] - Jinli Yongci confirmed that its recent stock price fluctuations are not due to undisclosed significant matters [20] Other Developments - Heng Rui Medicine's subsidiary received approval for clinical trials of SHR-1905 injection [24] - Renfu Medicine received a drug registration certificate for Dapoxetine Hydrochloride Tablets, which are expected to generate approximately 1.1 billion yuan in sales in 2024 [26]

Core Viewpoint - Shengnuo Bio (688117.SH) expects a significant increase in net profit for the first three quarters of 2025, projecting a range of 114 million to 140 million yuan, representing a year-on-year increase of 57.25 million to 82.63 million yuan, or 100.53% to 145.10% [1] Group 1 - The company's main business is experiencing stable development, contributing to overall performance growth [1] - The demand for orders in the peptide raw material business is continuously increasing due to the ongoing capacity expansion [1] - The substantial growth in performance allows the company to maintain strong market competitiveness and sustained profitability [1]

Core Viewpoint - Shengnuo Biotech (688117.SH) is expected to achieve significant growth in net profit for the first three quarters of 2025, indicating strong business performance and market competitiveness [1] Financial Performance - The company anticipates a net profit attributable to shareholders of approximately 114.20 million to 139.57 million yuan for the first three quarters of 2025, representing an increase of 57.25 million to 82.63 million yuan compared to the same period last year, which is a year-on-year growth of 100.53% to 145.10% [1] - The expected net profit after deducting non-recurring gains and losses is projected to be between 113.35 million and 138.54 million yuan, with an increase of 59.70 million to 84.89 million yuan year-on-year, translating to a growth rate of 111.26% to 158.21% [1] Business Development - The company's main business is steadily developing, with increasing demand for its peptide raw material business orders, contributing to overall performance improvement [1] - The continuous implementation of production capacity investments is driving the company's strong market competitiveness and sustained profitability [1]

Core Viewpoint - Shengnuo Bio (688117) expects a significant increase in net profit for the first three quarters of 2025, projecting a profit of between 114 million to 140 million yuan, representing a year-on-year growth of 100.53% to 145.1% [1] Group 1 - The company's main business has shown stable development during the reporting period [1] - The construction of production capacity is gradually being realized, contributing to overall performance improvement [1] - The demand for orders in the peptide raw material business continues to grow, enhancing market competitiveness and sustainable profitability [1]

Core Viewpoint - Shengnuo Biotech (SH 688117) expects a significant increase in net profit for the first three quarters of 2025, projecting a profit of approximately 114 million to 140 million yuan, representing a year-on-year increase of 100.53% to 145.1% [1] Financial Performance - The projected net profit increase of 57.25 million to 82.63 million yuan is attributed to stable development in the company's main business and growing demand for its peptide raw materials [1] - The company's revenue composition for 2024 is expected to be 98.91% from the pharmaceutical manufacturing sector and 1.09% from other businesses [1] Market Position - Shengnuo Biotech maintains strong market competitiveness and sustained profitability due to the substantial growth in its overall performance [1]

证券代码：688117 证券简称：圣诺生物 公告编号：2025-027 成都圣诺生物科技股份有限公司 2025 年前三季度业绩预告的自愿性披露公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、本期业绩预告情况 （一）业绩预告期间 二、上年同期业绩情况 公司上年同期归属于母公司所有者的净利润为 5,694.66 万元，归属于母公司 所有者扣除非经常性损益后的净利润为5,365.55万元，利润总额为6,392.10万元， 每股收益为 0.51 元。 三、本期业绩变化的主要原因 报告期内，公司主营业务稳定发展，随着投建产能不断落地，公司多肽原料 药业务订单需求持续增长，带动公司整体业绩稳步提升，与同期相比业绩实现较 大增长，使得公司保持较强的市场竞争力与持续盈利能力。 四、风险提示 1 2025 年 1 月 1 日至 2025 年 9 月 30 日。 （二）业绩预告情况 （1）经财务部门初步测算，成都圣诺生物科技股份有限公司（以下简称"公 司"）预计 2025 年前三季度实现归属于母公司所有者的净利润 11,419.66 ...

Core Viewpoint - Shengnuo Bio (688117.SH) expects a significant increase in net profit for the first three quarters of 2025, projecting a range of 114 million to 140 million yuan, representing a year-on-year growth of 100.53% to 145.10% [1] Group 1 - The company's main business is experiencing stable development, contributing to the overall performance improvement [1] - The construction of production capacity is gradually being realized, which supports the company's growth [1] - The demand for orders in the peptide raw material business continues to grow, enhancing the company's market competitiveness and sustainable profitability [1]